OakChart

Passage Bio Inc

PASGHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 11:19 AM ET

3.74-0.04 (-1.06%)
2026-11-11 17:27 CET
Market cap
12.16 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-33.08 USD m
Free cash flow, TTM
-32.65 USD m
EPS diluted, TTM
-10.34
P/E
-
Compare

Price

PASG against its 20, 50 and 200-day averages
2050200miss
4.006.008.00520K1.0MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PASGclose 3.7420-day 3.5250-day 4.13200-day 5.883.7452w low

81.3% under the 52-week high of 20.00 on 9 Jan 2026. 52-week low 3.29 on 25 Jun 2026. Last 15 sessions, 21.2% high to low

Profile

PASG
52-week range, 3% of the way up
3.2920.00

Passage Bio, Inc. operates as a genetic medicines company. It focuses on development of therapies for central nervous system disorders. The company was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.

Employees24
IPOFeb 28, 2020
Beta1.47
ATR, 14d0.31
Rel volume0.72
Short float1.67%
Insider own7.71%
Inst own43.75%

Snapshot

6 groups

Valuation

Index-
Market Cap12.03M
Enterprise Value-8.13M
Income-33.08M
Sales0.00M
Book/sh0.02
Cash/sh6.27
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees24
IPOFeb 28, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B240.67
P/C0.60
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio1.00
Current Ratio1.00
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-10.34
EPS next Y-3.91
EPS next Q-1.47
EPS this Y45.99%
EPS next Y49.55%
EPS next 5Y-
EPS past 3/5Y34.05% 24.41%
Sales past 3/5Y- -
EPS Y/Y TTM28.49%
Sales Y/Y TTM-
EPS Q/Q39.84%
Sales Q/Q-
EarningsJul 30
EPS/Sales Surpr.-7.49% -

Ownership

Insider Own7.71%
Insider Trans25.27%
Inst Own43.75%
Inst Trans-4.90%
ROA-69.68%
ROE-212.27%
ROIC-66164.00%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA206.29%
SMA50-9.35%
SMA200-36.40%
Trades-

Technical

Shs Outstand3.22M
Shs Float2.97M
Short Float1.67%
Short Ratio2.46
Short Interest0.05M
52W High20.00 -81.30%
52W Low3.29 13.68%
Volatility10.34% 8.67%
ATR (14)0.31
RSI (14)50.44
Beta1.47
Rel Volume0.72
Avg Volume20.14K
Volume4,822

Performance

Perf Week6.55%
Perf Month2.75%
Perf Quarter-18.25%
Perf Half Y-32.25%
Perf YTD-68.31%
Perf Year-51.43%
Perf 3Y-68.83%
Perf 5Y-97.81%
Perf 10Y-
Recom2.33
Target Price15.50
Prev Close3.78
Price3.74
Change %-1.06%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jun 10, 2026DowngradeGGuggenheimBuy → Neutral
Apr 21, 2026DowngradeWWedbushOutperform → Neutral$8+113.9%
Apr 21, 2026DowngradeTTD CowenBuy → Hold
Apr 21, 2026DowngradeCChardan Capital MarketsBuy → Neutral$7+87.2%
Mar 31, 2026InitiatedOOppenheimerOutperform$30+702.1%
Feb 10, 2026ResumedCChardan Capital MarketsBuy$21+461.5%
Nov 29, 2024ResumedWWedbushOutperform$3 → $4+7.0%
Sep 03, 2024InitiatedRRodman & RenshawBuy$7+87.2%
Mar 08, 2022DowngradeJJP MorganOverweight → Neutral
Jan 19, 2022DowngradeGGoldmanBuy → Neutral$29 → $6+60.4%

Peers

Mkt cap
TickerCompanyMkt cap
TSHATaysha Gene Therapies Inc1.39B
ALECAlector Inc407.18M
VYGRVoyager Therapeutics Inc110.46M
LXEOLexeo Therapeutics Inc258.17M
NGNENeurogene Inc532.01M
QUREuniQure NV1.63B
MGTXMeiraGTx Holdings plc931.04M
DNLIDenali Therapeutics Inc3.19B
ABEOAbeona Therapeutics Inc133.73M
SLDBSolid Biosciences Inc867.22M

Insider trading

4 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Lynx1 Capital Management LP10% OwnerJun 25 '26Buy4.1250,055206,101673,759Jun 29 04:30 PM
Chou WilliamPRESIDENT AND CEOJan 08 '26Sale18.444,07675,1596,524Jan 12 04:03 PM
Borthwick KathleenCFOJan 08 '26Sale18.442,06238,0225,402Jan 12 04:03 PM
Chou WilliamOfficerJan 09 '26Proposed Sale18.434,07675,120Jan 09 04:03 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 206
  • Remix to go public in reverse merger with once high-flying Passage Bio (BioPharma Dive) -26.36%
  • SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today (Stocktwits)
  • PASG Stock Slumps 16% After-Hours Whats Driving The Selloff? (Stocktwits)
  • Passage Bio and Remix Therapeutics Announce Merger Agreement (GlobeNewswire)
  • Intel upgraded, Reddit initiated: Wall Street's top analyst calls (The Fly)
  • Loading…
  • Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates (GlobeNewswire) -46.44%
  • Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights (GlobeNewswire) -8.88%
  • Passage Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights (GlobeNewswire) +6.68% +14.84%
  • Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference (GlobeNewswire)
  • Passage Bio to Participate in Chardan's 9th Annual Genetic Medicines Conference (GlobeNewswire)
  • Wall Street Analysts Think Passage Bio (PASG) Could Surge 731%: Read This Before Placing a Bet (Zacks)
  • Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-07-30-2.440-2.270-2.4370.000.001
2026Q12026-05-19-2.360-2.764-2.3580.000.005
2025Q42026-03-03-4.090-2.568-4.0790.000.005
2025Q32025-11-10-2.440-2.758-2.4380.000.004
2025Q22025-08-12-2.960-4.040-2.9620.000.005
2025Q12025-05-13-5.000-4.600-4.9610.000.004
2024Q42025-03-04-4.000-4.300-4.1010.000.006
2024Q32024-11-13-6.200-4.636-6.2630.001.676
2024Q22024-08-08-5.200-6.184-5.1850.000.005
2024Q12024-05-14-6.000-7.150-5.9370.000.004
2023Q42024-03-04-6.000-7.720-6.1000.000.005
2023Q32023-11-13-9.800-9.134-9.8960.000.006
2023Q22023-08-07-8.800-9.466-8.7250.000.006
2023Q12023-05-11-12.600-10.672-12.5740.000.009
2022Q42023-03-06-10.000-10.458-9.9130.000.009
2022Q32022-11-10-9.800-15.544-9.8030.000.008

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-44.534--19.9280.00-
2020FY-58.200-54.318-58.1270.000.00
2021FY-69.600-67.140-69.5060.000.00
2022FY-50.000-50.792-50.0190.000.00
2023FY-37.200-37.040-37.2870.000.00
2024FY-21.400-19.700-21.4440.000.00
2025FY-14.350-9.830-14.3500.000.00
2026FY--7.750--0.00
2027FY--3.910--0.00
2028FY--8.870--0.00
2029FY--10.180--0.00
2030FY--9.800--0.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-06-111000.000.000.00
2026Q3S2026-06-092000.000.000.00
2026Q3S2026-05-193000.000.000.00
2026Q3S2026-05-053000.000.000.00
2026Q3S2026-04-244000.000.000.00
2026Q3S2026-03-275000.000.000.00
2026Q3S2026-03-034000.000.000.00
2026Q3S2026-02-062000.000.000.00
2026Q3S2026-01-151000.000.000.00
2026Q3S2025-11-212000.000.000.00
2026Q3S2025-11-111000.000.000.00
2026Q3S2025-11-101000.000.000.00
2026Q3S2025-11-091000.000.000.00
2026Q3S2025-11-081000.000.000.00

Estimate history

EPS, annual-5.577-19.928-58.127-69.506-50.019-37.287-21.444-14.347-10.3409
Period20182019202020212022202320242025TTM
EPS, quarterly-6.263-4.101-4.961-2.962-2.438-4.079-2.358-2.437-1.467
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000000000
Period20182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual2.292.292.2812.7122.7312.7473.1033.1833.218
Period20182019202020212022202320242025MRQ
Shares, quarterly3.0883.1033.1073.1793.1793.1833.2083.2183.218
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.330.733.083.723.681.540.800.130.00
Gross Profit-0.33-0.73-3.08-3.72-3.68-1.54-0.80-0.130.00
Selling, General and Administrative Excl. Other33.8542.4262.0996.42125.61176.19111.1036.5510.10
Research and Development14.1523.2840.1859.5683.75117.6781.7929.749.17
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-34.18-43.15-65.17-100.14-129.29-177.73-111.90-36.69-10.10
Interest Expense0.000.000.000.000.000.000.000.000.00
Unusual Expense1.136.145.237.799.108.001.009.642.67
Net Income Before Taxes-33.08-45.52-64.77-102.06-136.12-185.39-112.23-45.63-12.77
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-33.08-45.52-64.77-102.06-136.12-185.39-112.23-45.63-12.77
Net Income From Continuing Operations-33.08-45.52-64.77-102.06-136.12-185.39-112.23-45.63-12.77
Net Income-33.08-45.52-64.77-102.06-136.12-185.39-112.23-45.63-12.77
EPS (Recurring)-10.03-12.99-20.23-35.30-47.68-67.41-57.76-16.98-4.76
EPS (Basic, Before Extraordinaries)-10.34-14.35-21.44-37.29-50.02-69.51-58.13-19.93-5.58
EPS (Diluted)-10.34-14.35-21.44-37.29-50.02-69.51-58.13-19.93-5.58
EBITDA-33.85-42.42-62.09-96.42-125.61-176.19-111.10-36.55-10.10
Non-Operating Income (Expense)2.233.775.635.862.270.340.670.700.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.003.005.8210.9218.9532.6914.581.45-
Shares Outstanding3.223.183.102.752.732.712.282.292.29
Market Capitalization12.1612.1635.2055.3675.27344.461,166.371,178.44-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.030.130.180.200.200.200.72
Gross Profit0.00-0.03-0.13-0.18-0.20-0.20-0.20-0.72
Selling, General and Administrative Excl. Other4.7410.198.7510.168.4610.1313.6213.55
Research and Development1.303.344.095.424.315.817.749.56
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-4.74-10.22-8.88-10.34-8.65-10.33-13.82-14.27
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.20-1.94-0.633.510.000.002.640.00
Net Income Before Taxes-4.72-7.82-7.56-12.98-7.75-9.38-15.40-12.72
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-4.72-7.82-7.56-12.98-7.75-9.38-15.40-12.72
Net Income From Continuing Operations-4.72-7.82-7.56-12.98-7.75-9.38-15.40-12.72
Net Income-4.72-7.82-7.56-12.98-7.75-9.38-15.40-12.72
EPS (Recurring)-1.42-2.86-2.50-3.31-2.44-2.96-4.37-4.10
EPS (Basic, Before Extraordinaries)-1.47-2.44-2.36-4.08-2.44-2.96-4.96-4.10
EPS (Diluted)-1.47-2.44-2.36-4.08-2.44-2.96-4.96-4.10
EBITDA-4.74-10.19-8.75-10.16-8.46-10.13-13.62-13.55
Non-Operating Income (Expense)0.220.450.690.860.910.951.051.25
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.310.530.560.610.610.920.861.25
Shares Outstanding3.223.223.213.183.183.183.113.10
Market Capitalization12.1615.6525.1836.8225.0625.4521.9435.20

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments46.3076.76114.29189.61315.77304.82158.8724.86
Short Term Receivables0.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets1.462.063.677.439.2912.376.908.54
Total Current Assets47.7678.81117.96197.04325.07317.18165.7833.40
Net Property, Plant & Equipment14.2823.1332.1542.2423.812.791.090.03
Total Investments and Advances0.000.000.000.000.000.000.000.00
Other Assets0.240.460.434.276.208.0311.750.03
Total Assets62.28102.41150.54243.55355.08328.01178.6133.46
Short Term Debt Incl. Current Port. of LT Debt3.573.693.373.270.000.000.000.00
Accounts Payable1.110.741.304.079.455.260.630.21
Other Current Liabilities18.4014.9311.6711.0120.0515.913.050.10
Total Current Liabilities23.0819.3616.3418.3529.5021.183.680.31
Long Term Debt20.4421.7922.9223.830.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.006.922.120.582.21
Total Liabilities43.5341.1539.2642.1836.4223.294.262.52
Non-Equity Reserves0.000.000.000.000.000.00230.6043.12
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity18.7561.26111.28201.37318.66304.71-56.25-12.17
Total Shareholders Equity18.7561.26111.28201.37318.66304.71-56.25-12.17
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity18.7561.26111.28201.37318.66304.71-56.25-12.17
Total Liabilities & Stockholders Equity62.28102.41150.54243.55355.08328.01178.6133.46
Book Value Per Share5.8919.7440.5173.74117.49133.60-24.57-5.32
Tangible Book Value Per Share5.8919.7440.5173.74117.49133.60-24.57-5.32
Full-Time Employees246058851337420-
Price to Book Ratio243.240.570.440.341.083.833.48-
Return on Assets-55.28-51.21-51.80-45.48-54.28-44.31-43.04-
Return on Equity-113.78-75.07-65.29-52.35-59.48-90.34--
Return on Invested Capital-116.13-77.99-76.05-60.45-58.18-36.83--
Quick Ratio2.074.077.2210.7411.0214.9845.04108.79
Current Ratio2.074.077.2210.7411.0214.9845.04108.79

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-33.08-45.52-64.77-102.06-136.12-185.39-112.23-45.63-12.77
Depreciation0.330.733.083.723.681.540.800.130.00
Other Funds (Non Cash)2.939.299.5314.7422.7345.5416.4711.552.73
Funds from Operations-29.82-35.51-52.16-83.60-109.72-138.30-94.96-33.95-10.04
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-2.834.004.205.34-8.4911.4214.44-5.94-8.52
Cash from Operating Activities-32.65-31.51-47.96-78.26-118.21-126.88-80.52-39.90-18.57
Capital Expenditures0.000.00-0.03-0.15-5.27-25.64-1.65-1.69-2.54
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.021.170.000.000.000.000.000.000.00
Purchase or Sale of Investments0.0039.0554.9865.3830.47-20.17-170.460.000.00
Purchase of Investments0.000.00-88.17-129.43-157.84-202.55-266.060.000.00
Sale Or Maturity of Investments0.0039.05143.15194.81188.31182.3795.600.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.0240.2254.9565.2425.20-45.81-172.11-1.69-2.54
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.010.028.870.140.43166.66228.75175.6045.97
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.010.028.870.140.43166.66228.75175.6045.97
Proceedsfrom Stock Options0.010.028.840.140.30166.35228.55175.4345.97
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.00-1.790.000.000.000.00
Other Financing Activities Uses0.000.000.000.00-1.790.000.000.000.00
Cash from Financing Activities0.010.028.870.14-1.35166.66228.75175.6045.97
Net Change in Cash-32.618.7315.86-12.89-94.36-6.04-23.87134.0124.86
Free Cash Flow-32.65-31.51-47.99-78.41-123.48-152.52-82.17-41.59-21.11
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments20.1624.1633.3446.3052.7757.63
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.631.021.411.462.962.69
Total Current Assets20.7925.1834.7447.7655.7360.31
Net Property, Plant & Equipment0.000.001.4814.2818.1618.61
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.00----
Other Assets0.000.000.240.240.270.27
Total Assets20.7925.1836.4662.2874.1679.20
Short Term Debt Incl. Current Port. of LT Debt0.000.001.153.573.543.59
Accounts Payable0.530.901.311.110.952.40
Other Current Liabilities20.2119.8217.6418.4017.7513.81
Total Current Liabilities20.7420.7220.1023.0822.2519.80
Long Term Debt0.000.004.6120.4420.8021.14
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities20.7420.7224.7143.5343.0440.94
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity0.054.4611.7518.7531.1238.26
Total Shareholders Equity0.054.4611.7518.7531.1238.26
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity0.054.4611.7518.7531.1238.26
Total Liabilities & Stockholders Equity20.7925.1836.4662.2874.1679.20
Book Value Per Share0.021.383.665.899.7912.04
Tangible Book Value Per Share0.021.383.665.899.7912.04
Full-Time Employees---24--
Price to Book Ratio243.241.331.331.210.670.67
Return on Assets-69.68-69.20-61.53-55.28-48.69-55.58
Return on Equity-212.27-169.09-128.90-113.78-87.18-88.27
Return on Invested Capital-9,438.00-175.52-46.21-33.12-14.93-15.80
Quick Ratio1.001.221.732.072.513.05
Current Ratio1.001.221.732.072.513.05

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-4.72-7.82-7.56-12.98-7.75-9.38
Depreciation0.000.030.130.180.180.17
Other Funds (Non Cash)0.31-1.42-0.084.120.610.94
Funds from Operations-4.41-9.21-7.51-8.69-6.96-8.28
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.410.03-5.482.212.101.95
Cash from Operating Activities-4.00-9.18-12.99-6.48-4.85-6.33
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.020.000.000.58
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.020.000.000.58
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.000.010.000.01
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.000.010.000.01
Proceedsfrom Stock Options0.000.000.000.010.000.01
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.000.000.000.010.000.01
Net Change in Cash-4.00-9.18-12.97-6.47-4.85-5.73
Free Cash Flow-4.00-9.18-12.99-6.48-4.85-6.33

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.67%0.0M3.0M19.59K
2026-10-152.32%0.1M3.0M23.81K
2026-09-303.06%0.1M3.0M28.32K
2026-09-153.27%0.1M3.0M65.75K
2026-08-313.42%0.1M3.0M66.49K
2026-08-144.61%0.1M3.0M69.57K
2026-07-315.26%0.2M3.0M82.68K
2026-07-154.21%0.1M3.0M114.38K
2026-06-303.86%0.1M3.0M113.63K
2026-06-152.90%0.1M3.2M76.79K
2026-05-293.92%0.1M3.1M79.62K
2026-05-155.23%0.2M3.1M77.86K
2026-04-304.66%0.1M3.1M71.49K
2026-04-152.20%0.1M3.1M43.83K
2026-03-313.69%0.1M3.1M57.52K
2026-03-133.17%0.1M3.1M59.19K
2026-02-272.95%0.1M3.1M58.41K
2026-02-133.04%0.1M3.0M61.75K
2026-01-300.38%0.0M3.0M60.52K
2026-01-150.51%0.0M3.0M58.11K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-068-KCurrent report2026-11-05SEC
2026-10-09EFFECTEffectiveness filing by commission orderSEC
2026-10-09424B3SEC
2026-10-08S-4/ASEC
2026-10-05S-4/ASEC
2026-09-21S-4/ASEC
2026-09-03S-4/ASEC
2026-09-03425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-09-038-KCurrent report2026-09-02SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-22425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-07-21S-4Registration statement for securities to be issued in business combination transactionsSEC
2026-07-02SCHEDULE 13DSEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-25SCHEDULE 13GSEC
2026-06-24425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-06-24425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-06-248-KCurrent report2026-06-23SEC
2026-05-278-KCurrent report2026-05-21SEC
2026-05-268-KCurrent report2026-05-19SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-288-KCurrent report2026-04-28SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-06206.10K100
2026-050000
2026-040000
2026-030000
2026-020000
2026-0100113.18K2
2025-120000
2025-110000

Institutional holders

Manager% owned
Lynx1 Capital Management LP21.00%
VANGUARD CAPITAL MANAGEMENT LLC3.55%
BALYASNY ASSET MANAGEMENT L.P.3.34%
Ikarian Capital, LLC3.10%
Yiheng Capital Management, L.P.2.68%
RENAISSANCE TECHNOLOGIES LLC1.49%
Erste Asset Management GmbH1.27%
GEODE CAPITAL MANAGEMENT, LLC1.15%
Verdad Advisers, LP0.96%
BOOTHBAY FUND MANAGEMENT, LLC0.89%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.46%
VANGUARD EXTENDED MARKET INDEX FUND1.10%
Fidelity Extended Market Index Fund0.53%
Fidelity Total Market Index Fund0.20%
Fidelity Series Total Market Index Fund0.15%
LVIP Dimensional U.S. Core Equity 2 Fund0.06%
U.S. CORE EQUITY 2 PORTFOLIO0.05%
Fidelity Nasdaq Composite Index Fund0.04%
Dimensional US Core Equity 1 ETF0.04%
U.S. Social Core Equity 2 Portfolio0.03%

OakChart. PASG. Cached 15 minutes.